Formalin-fixed, paraffin-embedded (FFPE) tissues are a vast and invaluable source of information for disease research, particularly in the field of cancer. Due to fixation and storage processes, RNA obtained from FFPE samples can suffer from high levels of degradation, resulting in unreliable and inaccurate gene expression profiles and higher sequencing depth requirements. To overcome these challenges, TruSeq Exome RNA sequencing was developed. The benefits of TruSeq Exome RNA sequencing include the ability to generate robust gene expression profiles using RNA from FFPE and low-quality samples. In addition, TruSeq Exome RNA sequencing requires less RNA and less sequencing depth than standard mRNA sequencing, thus enabling more cost-effective transcriptome analysis. Novogene’s clinical TruSeq Exome RNA sequencing is ensured by streamlined and standardised protocols, as well as strict quality controls throughout the workflow.
System that meets the requirements of national and international standards, including CAP accreditation
Higher performance than standard polyA enrichment mRNA sequencing, with higher Q30 values, lower rRNA%, and higher percentage of clean reads.
Data covering gene expression quantification, differential expression and enrichment analysis, and various advanced analysis options
Publication-ready results and bioinformatic consultants available for data interpretation
The field is required.